YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma

[1]  Wei Zhang,et al.  Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma , 2011, Cancer.

[2]  C. Napoli,et al.  Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer , 2011, International journal of cancer.

[3]  Chi-kong Li,et al.  Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival , 2011, Pediatric Radiology.

[4]  M. Hurt,et al.  The Transcription Factor YY1 Is a Substrate for Polo-Like Kinase 1 at the G2/M Transition of the Cell Cycle , 2011, PloS one.

[5]  C. Napoli,et al.  CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy , 2010, Proceedings of the National Academy of Sciences.

[6]  E. Pignotti,et al.  Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Squire,et al.  Open Access Research Article Expression Analysis of Genes Associated with Human Osteosarcoma Tumors Shows Correlation of Runx2 Overexpression with Poor Response to Chemotherapy , 2022 .

[8]  D. Spandidos,et al.  Yin Yang 1 expression in human tumors , 2010, Cell cycle.

[9]  M. Tainsky,et al.  Genomic and proteomic biomarkers for cancer: a multitude of opportunities. , 2009, Biochimica et biophysica acta.

[10]  Y. Shimoyama,et al.  Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma , 2009, Clinical & Experimental Metastasis.

[11]  J. Roh,et al.  Clinical value of ezrin expression in primary osteosarcoma. , 2009, Cancer research and treatment : official journal of Korean Cancer Association.

[12]  Baoying Huang,et al.  Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells , 2009, Molecular Cancer Research.

[13]  D. Jeon,et al.  Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  C. Andry,et al.  Transcription factor YY1 expression in human gastrointestinal cancer cells. , 2009, International journal of oncology.

[15]  Y. Iwamoto,et al.  Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft‐tissue sarcoma , 2009, International journal of cancer.

[16]  N. Ishiguro,et al.  Cyclooxygenase-2 Overexpression Predicts Poor Survival in Patients with High-grade Extremity Osteosarcoma: A Pilot Study , 2009, Clinical orthopaedics and related research.

[17]  Jeffrey T. Chang,et al.  Yin Yang 1 Modulates Taxane Response in Epithelial Ovarian Cancer , 2009, Molecular Cancer Research.

[18]  Mads Thomassen,et al.  Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer , 2008, BMC Cancer.

[19]  T. Daniels,et al.  Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells1 , 2008, The Journal of Immunology.

[20]  C. Napoli,et al.  Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. , 2008, Cancer research.

[21]  P. Choong,et al.  A review of clinical and molecular prognostic factors in osteosarcoma , 2008, Journal of Cancer Research and Clinical Oncology.

[22]  J. Berkhof,et al.  Human papillomavirus testing on self‐sampled cervicovaginal brushes: An effective alternative to protect nonresponders in cervical screening programs , 2007, International journal of cancer.

[23]  C. Napoli,et al.  Expression of transcription factor Yin Yang 1 in human osteosarcomas. , 2006, European journal of cancer.

[24]  G. Bacci,et al.  Primary bone osteosarcoma in the pediatric age: state of the art. , 2006, Cancer treatment reviews.

[25]  B. Bonavida,et al.  Involvement of the TNF-α autocrine–paracrine loop, via NF-κB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis , 2006 .

[26]  N. Nemoto,et al.  Survivin as a Prognostic Factor for Osteosarcoma Patients , 2006, Acta histochemica et cytochemica.

[27]  Piero Picci,et al.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.

[28]  B. Bonavida,et al.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology , 2006, Oncogene.

[29]  S. Horvath,et al.  Expression of transcription factor Yin Yang 1 in prostate cancer. , 2005, International journal of oncology.

[30]  A. Huvos,et al.  Messenger RNA Expression Levels of CXCR4 Correlate with Metastatic Behavior and Outcome in Patients with Osteosarcoma , 2005, Clinical Cancer Research.

[31]  S. Ferrari,et al.  Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Picci,et al.  Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. , 1995, The New England journal of medicine.

[33]  R. Marcove,et al.  Osteoid osteoma. Diagnosis, localization, and treatment. , 1991, Clinical orthopaedics and related research.

[34]  E. Davicioni,et al.  Diagnostic and prognostic sarcoma signatures. , 2008, Molecular diagnosis & therapy.

[35]  C. Napoli,et al.  Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha3beta1-integrin in tumour cells. , 2007, Oncogene.

[36]  B. Bonavida,et al.  Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. , 2006, Clinical immunology.

[37]  S. Ferrari,et al.  Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. , 2002, Oncology reports.

[38]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.